Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 5/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | GLA | P06280 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626821 | 1.00 | ALDH1A1 (0.62) | ALDH1A1ABL1RIN1LMNAHTT | |
| SCHEMBL18887599 | 0.89 | TSHR (0.56) | ALDH1A1ABL1RIN1LMNAGAA | |
| SCHEMBL17124777 | 0.87 | JAK2 (0.55) | ALDH1A1ABL1RIN1LMNAHTT | |
| SCHEMBL9000738 | 0.87 | ABL1 (0.49) | ALDH1A1ABL1RIN1LMNAHTT | |
| SCHEMBL9000521 | 0.87 | ABL1 (0.52) | ALDH1A1ABL1RIN1LMNAHTT | |
| SCHEMBL2987951 | 0.86 | NPSR1 (0.48) | ALDH1A1ABL1RIN1LMNAHTT | |
| SCHEMBL3759057 | 0.86 | GAA (0.53) | ALDH1A1ABL1RIN1LMNANPC1 | |
| SCHEMBL2094025 | 0.86 | GAA (0.53) | ALDH1A1ABL1RIN1EPHX2GAA | |
| SCHEMBL13813952 | 0.86 | ALDH1A1 (0.53) | ALDH1A1ABL1RIN1LMNANPC1 | |
| SCHEMBL30094581 | 0.86 | GAA (0.53) | ALDH1A1ABL1RIN1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 207 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033006-B | Preparation method of diaryl ketone | 长沙理工大学 | 2018-12-18 | — | — | CN | claimed |
| CN-107033006-A | Preparation method of diaryl ketone | 长沙理工大学 | 2017-08-11 | — | — | CN | claimed |
| CN-102924318-B | L-leucine derivatives blocking entrance of H5N1 avian influenza virus and preparation method for same | UNIV WUHAN | 2014-06-04 | — | — | CN | claimed |
| CN-102924318-A | L-leucine derivatives blocking entrance of H5N1 avian influenza virus and preparation method for same | UNIV WUHAN | 2013-02-13 | — | — | CN | claimed |
| EP-4734977-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | Neucures, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4616906-A2 | BENZO[A]PHENANTHRIDINE DERIVATIVES AS YAP/TAZ INHIBITORS | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2025-06-19 | — | — | US | disclosed |
| WO-2025006675-A9 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025006675-A2 | NOVEL TRPV1 AGONISTS AND USES THEREOF | NEUCURES, INC. (US) | 2025-01-02 | — | — | WO | disclosed |
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | MILESTONE PHARMACEUTICALS INC (CA) | 2024-11-07 | — | — | US | disclosed |
| WO-2024183784-A1 | PHARMACEUTICAL USE OF TROPIC ACID AND DERIVATIVES THEREOF IN PREPARATION OF DRUG FOR TREATING IMMUNE- AND INFLAMMATION-RELATED DISEASES | 广东药科大学 | 2024-09-12 | — | — | WO | disclosed |
| WO-2024088153-A1 | USE OF TROPIC ACID AND DERIVATIVE THEREOF IN PREPARATION OF DRUG FOR TREATING PSORIASIS | 广东药科大学 | 2024-05-02 | — | — | WO | disclosed |
| EP-0611003-A1 | Substituted phenyl sulfonamides as selective B3 agonists for the treatment of diabetes and obesity | MERCK & CO. INC. (US) | 1994-08-17 | — | — | EP | disclosed |
| US-RE34630-E | Antagonist for platelet activating factor | EUROCELTIQUE, S.A. (LU) | 1994-06-07 | — | — | US | disclosed |
| US-5243066-A | ALKYL 2-ARYL-2,2-DIALKOXYACETATES, THE PREPARATION THEREOF AND A METHOD OF USING THEM FOR PREPARING ARYLGLYOXYLIC ESTERS | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-07 | — | — | US | disclosed |
| US-5219848-A | Bactericides | ICI PHARMA (FR) | 1993-06-15 | — | — | US | disclosed |
| EP-0422328-A2 | Substituted isoquinolines and their use | Euro-Celtique S.A. (LU) | 1991-04-17 | — | — | EP | disclosed |
| EP-0412763-A2 | Cephalosporins, processes for their preparation, pharmaceutical compositions containing them and intermediates therefor | ZENECA LIMITED (GB) | 1991-02-13 | — | — | EP | disclosed |
| US-4956371-A | PLATELET ACTIVATING FACTOR | EUROCELTIQUE, S.A. (LU) | 1990-09-11 | — | — | US | disclosed |
| US-3936457-A | VASODILATION | WARNER-LAMBERT COMPANY (US) | 1976-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366552-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ALDH1A1 3189/4885ABL1 1470/4885RIN1 4325/4885 |
| US-20250195462-A1 | SHORT ACTING PHENYLALKYLAMINE CALCIUM CHANNEL BLOCKERS AND USES THEREOF | ORAI1, ATP2A1, RYR2 | ALDH1A1 3189/4885ABL1 1470/4885RIN1 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.